1. Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

3. Activity Goals

4. Comparison of Conventional Cytogenetics, FISH, and Molecular Studies

5. TKIs For the Treatment of CML

6. Response Rates With Dasatinib, Nilotinib

7. Factors Influencing Response to Therapy

8. Safety Profile of Imatinib, Dasatinib, Nilotinib

9. Overall Survival per Sokal Score

10. Treatment-Free Remission Years After Stopping Imatinib Treatment

11. Role of Pharmacist in Cancer Care

12. Drug-Drug Interactions With TKIs

13. Role of Nurse Practitioner in Cancer Care

15. Monitoring Response to Therapy

16. When to Change Therapy

17. Response Criteria

18. Treatment Based on BCR-ABL Mutational Analyses

19. Addressing Adverse Events in CML Disease Management

20. Addressing AEs in CML Disease Management — Non-Hematologic

21. Communication With Patients

22. Conclusions

23. Abbreviations

24. Abbreviations (cont)

25. References

26. References (cont)

27. References (cont)

28. References (cont)

29. References (cont)

30. References (cont)

31. References (cont)

32. References (cont)

33. References (cont)